



NDA 202570/S-018

**SUPPLEMENT APPROVAL/  
FULFILLMENT OF POSTMARKETING REQUIREMENT**

PF PRISM C.V.  
Attention: J. Nicole Earnhardt, Ph.D., RAC  
Senior Manager, Worldwide Safety & Regulatory  
Pfizer, Inc.  
10646 Science Center Drive  
San Diego, CA 92121

Dear Dr. Earnhardt:

We refer to your New Drug Application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for XALKORI (crizotinib) Capsules, 250 mg and 200 mg.

We have received your submission dated October 29, 2015, containing the final report for the following postmarketing requirement listed in the August 26, 2011, approval letter.

1789-7: Conduct a multiple dose trial in patients to determine how to adjust the crizotinib dose when it is coadministered with a strong CYP3A inducer (*e.g.*, rifampin).

We have reviewed your submission and conclude that the above requirement has been fulfilled.

We also refer to your supplemental New Drug Application (sNDA) dated November 20, 2015, received November 20, 2015, and your amendments. This Prior Approval supplemental new drug application proposes to update the Clinical Pharmacology, Pharmacokinetics subsection of the package insert with data derived from Postmarketing Requirement (PMR) 1789-7 involving a multiple-dose crizotinib drug interaction study of CYP3A inducers. .

**WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.”

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ingrid Fan, Regulatory Project Manager, at (301) 796-5053.

Sincerely,

*{See appended electronic signature page}*

Jeffery Summers, M.D.  
Deputy Director for Safety  
Division of Oncology Products 2  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JEFFERY L SUMMERS  
04/28/2016